Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer

By afschroeder • April 23, 2026

Fakih M, Gill S, Sampat K, Chan DL, Fisher G, Cruz-Correa M, Lenz HJ, Garcia-Alfonso P, Forget F, Lonardi S, Krauss J, Chen E, Cubillo Gracian A, Liu Y, van Buuren N, Shao J, Dong M, Chen A, Tejani M, Hecht JR. Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer. ESMO Gastrointest Oncol. 2026 Apr 17;12:100324. doi: 10.1016/j.esmogo.2026.100324. PMID: 42022129; PMCID: PMC13098452.

Tags: Bevacizumab, FOLFIRI, Hematology/Oncology, magrolimab, Metastatic colorectal cancer, Publications

Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results

Hochman MJ, Ruppert AS, Huang Y, Mims A, Borate U, Swords R, Traer E, Baer MR, Duong VH, Stock W, Odenike T, Patel P, Madanat[...]

Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease

Prueksapraopong C, Fernandes A, Campo Fernandez B, Roy S, Hollis RP, Habtemariam B, Pellin D, Ceoldo G, Lin TY, Dang TT, Cornetta K, Romero Z,[...]

Sustained Effects of a 6-Week Resiliency Program for Women with Metastatic Breast Cancer: A Brief Report of a Clinical Trial

Henneghan A, Wertheimer J, Kim S, Gresham G, Shirazipour CH, Jones B, Asher A. Sustained Effects of a 6-Week Resiliency Program for Women with Metastatic[...]